Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04895696 | A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | PHASE2 | ACTIVE NOT_RECRUITING | 268 | — | — | Oct 11, 2021 | Apr 22, 2029 | May 14, 2026 | 147 | United States, Argentina +17 |
| Arm | Type | Description |
|---|---|---|
| Afimetoran: Dose 1 | EXPERIMENTAL | - |
| Afimetoran: Dose 2 | EXPERIMENTAL | - |
| Afimetoran: Dose 3 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Afimetoran | DRUG | Specified dose on specified days |
| Placebo | OTHER | Specified dose on specified days |
Inclusion Criteria: * Diagnosed ≥ 12 weeks before the screening visit and qualify as having SLE according to the SLE International Collaborating Clinics (SLICC) Classification Criteria at the screening visit * Test positive, as determined by the central laboratory, for at least one of the following...